9 results about "Blood creatinine" patented technology

The invention provides a traditional Chinese medicine composition for treating nephropathy as well as a preparation method and application thereof, and the anti-renal fibrosis effect is remarkably improved by optimizing a leech extraction process and a novel preparation technology. Animal experiments show that urine protein of model animals can be reduced by 67% and serum creatinine can be reduced by 42% after 12 weeks of continuous administration. Clinical tests prove that the traditional Chinese medicine composition has a definite curative effect on IgA nephropathy, membranous nephropathy and the like, and a new choice is provided for treating chronic kidney diseases.

The invention belongs to the technical field of reproductive medicine and clinical metabolism intervention, and particularly relates to a group of markers for diagnosing unexplained recurrent abortion and application thereof. Aiming at the clinical pain point that unexplained recurrent abortion (URSA) lacks accurate metabolic typing diagnosis indexes and targeted treatment means, based on detection of a large number of clinical samples and verification of cell experiments, direct association between down-regulation of levels of choline related metabolites and trimethylamine oxide (TMAO) of decidua tissues and the RSA is disclosed for the first time; the core effect of TMAO in-situ synthesis of decidua stromal cells (DSC) in regulation and control of the decidualization process is determined; meanwhile, an RSA indication screening system of joint detection of serum creatinine and decidua choline metabolism is constructed, a targeted TMAO targeted intervention scheme is formed in a matched mode, a diagnosis and treatment closed loop of RSA from precise typing to targeted treatment is achieved, and a brand new technical path is provided for clinically solving the URSA diagnosis and treatment problem.

This invention relates to the field of biomedical technology, and more particularly to a biomarker set, staging model, and their applications for chronic kidney disease. This invention utilizes metabolomics data analysis to obtain a biomarker set based on serum creatinine. Then, through methodological optimization, a staging model for chronic kidney disease is constructed. This staging model is also used for staging chronic kidney disease, and the results are accurate, specific, precise, and highly sensitive. It eliminates the false positive problem of traditional serum creatinine-based methods and removes the influence of gender factors. Staging chronic kidney disease based on this model is more consistent with the disease's progression characteristics.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a kidney-protecting and blood stasis-removing mixture and a preparation method and application thereof. The kidney-protecting and blood stasis-eliminating mixture is composed of astragalus membranaceus, angelica sinensis, rhizoma bletillae, plantain herb, peach kernel, cooked rhubarb and scalded leech, the selected medicinal materials are appropriate in compatibility, the traditional Chinese medicine theory and the modern medicine theory are met, and the kidney-protecting and blood stasis-eliminating mixture has the effects of promoting blood circulation to remove blood stasis, tonifying kidney and spleen and eliminating dampness and heat. The kidney-protecting and blood stasis-eliminating mixture disclosed by the invention has remarkable curative effects on reducing serum creatinine, improving symptoms of chronic renal failure and acute renal failure, improving the life quality of patients and the like.

The invention discloses a pharmaceutical composition for treating chronic kidney disease stage 1-3 as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The composition consists of 40-60 parts of astragalus membranaceus, 40-60 parts of black soybeans, 8-12 parts of angelica sinensis, 24-36 parts of dogwood and 8-12 parts of rhodiola rosea. The preparation method comprises the following steps: pretreating the raw materials, soaking, boiling for several times and filtering to obtain a finished product. Based on the treatment principles of tonifying qi, activating blood, dredging collaterals and removing blood stasis in traditional Chinese medicine, the traditional Chinese medicine composition conforms to the pathogenesis of chronic kidney disease deficiency in root and excess in superficies, all the components synergistically play a role, the serum urea nitrogen, serum creatinine level and glomerular filtration rate of a patient can be improved and edema, weakness and other symptoms can be relieved by combining basic treatment, the total effective rate reaches 83.33%, and the traditional Chinese medicine composition is good in safety, easy and convenient to prepare and suitable for clinical application. The traditional Chinese medicine composition is suitable for long-term administration of patients with spleen and kidney qi deficiency and blood deficiency with stasis syndrome type chronic kidney diseases at 1-3 stages, and has good application value in treatment of related diseases.

The invention discloses an application of hexacosanol in preparation of a medicine for relieving and / or treating chronic kidney disease. Relates to the technical field of medicine products. It is found and proved for the first time that hexacosanol can effectively reduce serum creatinine (Scr) and urea nitrogen (BUN) levels of chronic kidney disease model animals and improve kidney pathological injuries, and shows a remarkable kidney protection effect. Besides, the invention provides a series of products containing hexacosanol, including pharmaceutical compositions for treating and / or relieving chronic kidney diseases and health products for assisting in improving and / or maintaining kidney health, and brand-new and safe natural active ingredient choices are provided for treatment and auxiliary management of chronic kidney diseases.

This invention belongs to the field of pet food processing and relates to a premix for improving the urinary tract health of pets. The premix contains the following components in parts by weight: 25-35 parts of Dioscorea opposita, 25-35 parts of Poria cocos, 15-25 parts of Taraxacum mongolicum, 15-25 parts of Centella asiatica, 15-25 parts of Plantago asiatica, 5-15 parts of Polygonatum sibiricum, 5-15 parts of Cornus officinalis, and 5-15 parts of Lycium barbarum. Adding this premix to the cat's diet reduces serum creatinine, blood urea nitrogen, and serum oxalate concentrations, affecting oxalate absorption and excretion, and preventing the formation of calcium oxalate stones. This premix can alleviate the nephrotoxicity of sodium oxalate in cats, improve renal physiological indicators, reduce the formation of calcium oxalate stones, and provide a basic guarantee for the treatment of chronic urinary system diseases. This premix can improve the urinary tract health of cats.

The invention relates to the technical field of biomedical treatment, in particular to a marker set for chronic kidney diseases, a staging model and application of the marker set and the staging model. According to the method, a marker set based on serum creatinine is obtained through metabonomics data analysis, then the staging model for staging the chronic kidney disease is constructed through methodological optimization, the staging model is used for staging the chronic liver disease, the result is accurate, specificity, precision and sensitivity are high, and the method is suitable for clinical application. The original false positive problem based on serum creatinine indexes is solved, the influence of gender factors is eliminated, and chronic kidney disease staging according to the staging model is more in line with the development characteristics of diseases.

The application discloses a preparation method and application of an autologous mitochondrion preparation, relates to the technical field of kidney protection and regeneration, and is characterized in that the mitochondrion is derived from heart tissue of a healthy C57 mouse of 8-10 weeks old, is obtained through a kit combined with a differential centrifugation method, and is characterized in that the obtained mitochondrion is continuous in outer membrane and clear in ridge structure under an electron microscope, and has good structural and functional integrity. In an in-vivo experiment, the mitochondrion is delivered to the renal cortex region of a recipient mouse through a subcapsular injection method 30 minutes before ischemia-reperfusion, and the result shows that the blood creatinine and urea nitrogen levels can be significantly reduced, the necrosis and oxidative stress damage of renal tubular epithelial cells can be reduced, and the renal tissue pathological score can be improved. The application provides a repeatable and standardizable organelle treatment strategy for intervention of kidney transplantation and acute kidney injury related IRI.